Want to see BLTE full AI Analyst Report?

Belite Bio, Inc. ADR (BLTE) Price & Analysis

67 Followers

BLTE Stock Chart & Stats

$156.69

$5.07(3.31%)

At close: Jul 27 4:00 PM EDT

$156.69

$5.07(3.31%)

Day’s Range― - ―

52-Week Range$64.00 - $200.00

Previous Close$157.3

Volume136.54K

Average Volume (3M)166.64K

Market Cap

$6.47B

Enterprise Value$5.30K

Total Cash (Recent Filing)$0.00

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.78

Next Earnings

Nov 17, 2026

EPS Estimate

-0.8

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.55

Shares Outstanding40,272,144

10 Day Avg. Volume140,964

30 Day Avg. Volume166,637

Financial Highlights & Ratios

PEG Ratio-0.72

Price to Book (P/B)6.96

Price to Sales (P/S)0.00

P/FCF Ratio-144.35

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$230.43

Price Target Upside47.06% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-3.24

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Regulatory Progress And Clinical EfficacyPriority Review and positive Phase 3 results materially advance tinlarebant toward commercialization. Potential first-mover status in STGD1 could support durable market access if approval is secured.

Strong, Low-Leverage Balance SheetMinimal debt and substantial liquidity provide financial flexibility to fund late-stage trials, regulatory work and launch preparation without near-term balance-sheet pressure or heavy interest obligations.

Expanding Late-Stage PipelineMultiple late-stage programs and geographic expansion create potential additional indications and markets beyond STGD1. This broadens the long-term opportunity set and may reduce reliance on one initial product.

Bears Say

Pre-Revenue Business ModelBLTE has no commercial revenue to offset research and launch costs, leaving its economic model dependent on successful approval, market adoption and future financing until product sales begin.

Escalating Operating BurnHigher clinical, commercial and staffing expenses are strategically understandable but increase cash consumption before approval. Continued spending growth could shorten runway or require capital if commercialization is delayed.

Manufacturing Execution UncertaintyLimited disclosure on contract manufacturers and inspection status leaves unresolved execution risk ahead of a potential launch. Manufacturing findings or remediation could delay approval, supply readiness or commercialization.

Belite Bio, Inc. ADR News

Canaccord starts Belite Bio at Buy on additional post-IPO upside

Canaccord analyst Whitney Ijem initiated coverage of Belite Bio (BLTE) with a Buy rating and $303 price target...

7m ago

BLTE

Belite Bio initiated with a Buy at Canaccord

Canaccord initiated coverage of Belite Bio (BLTE) with a Buy rating and $303 price target Published first on...

1h ago

BLTE

Belite Bio price target raised to $206 from $201 at Morgan Stanley

Morgan Stanley analyst Judah Frommer raised the firm’s price target on Belite Bio (BLTE) to $206 from $201...

18d ago

BLTE

Belite Bio announces FDA acceptance, priority review of tinlarebant NDA

Belite Bio (BLTE) announced that the FDA has accepted and granted Priority Review designation of the NDA for...

18d ago

BLTE

Belite Bio price target raised to $214 from $200 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen raised the firm’s price target on Belite Bio (BLTE) to $214 from $200...

18d ago

BLTE

Belite Bio reports Q2 EPS (54c), consensus (78c)

As of June 30, the company had $279.9M in cash and cash equivalents, compared with $352.9M on December...

18d ago

BLTE

Morning Movers: Cerebras slides following quarterly results

Stock futures are modestly higher as investors digest softer-than-feared Producer Price Index data that follows yesterday’s July CPI...

18d ago

Belite Bio price target raised to $220 from $215 at Mizuho

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Belite Bio (BLTE) to $220 from $215 and...

19d ago

BLTE

Belite Bio price target raised to $270 from $266 at Cantor Fitzgerald

Cantor Fitzgerald analyst Steve Seedhouse raised the firm’s price target on Belite Bio (BLTE) to $270 from $266...

19d ago

BLTE

Belite Bio price target raised to $206 from $201 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Belite Bio (BLTE) to $206 from $201 and keeps an...

19d ago

BLTE

Belite Bio Earnings Call Highlights Tinlarebant Momentum

Belite Bio, Inc. ADR (($BLTE)) has held its Q2 earnings call. Read on for the main highlights of...

8d ago

BLTE

Belite Bio Gains FDA Priority Review for Tinlarebant as Losses Widen on Commercial Build-Out

The latest announcement is out from Belite Bio, Inc. ADR ( ($BLTE) ). On August 12, 2026, Belite...

22d ago

BLTE

Yi Chen Raises Approval Odds and Lifts Tinlarebant-Focused 12‑Month Price Target to $214 While Reiterating Buy Rating

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Belite Bio, Inc. ADR and increased the...

23d ago

BLTE

Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease

Belite Bio, Inc. ADR ( ($BLTE) ) has provided an announcement. On August 11, 2026, Belite Bio announced...

24d ago

BLTE

BLTE FAQ

What was Belite Bio, Inc. ADR’s price range in the past 12 months?

Belite Bio, Inc. ADR lowest stock price was $64.00 and its highest was $200.00 in the past 12 months.

What is Belite Bio, Inc. ADR’s market cap?

Belite Bio, Inc. ADR’s market cap is $6.47B.

When is Belite Bio, Inc. ADR’s upcoming earnings report date?

Belite Bio, Inc. ADR’s upcoming earnings report date is Nov 17, 2026 which is in 74 days.

How were Belite Bio, Inc. ADR’s earnings last quarter?

Belite Bio, Inc. ADR released its earnings results on Aug 13, 2026. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.777 by $0.077.

Is Belite Bio, Inc. ADR overvalued?

According to Wall Street analysts Belite Bio, Inc. ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Belite Bio, Inc. ADR pay dividends?

Belite Bio, Inc. ADR does not currently pay dividends.

What is Belite Bio, Inc. ADR’s EPS estimate?

Belite Bio, Inc. ADR’s EPS estimate is -0.8.

How many shares outstanding does Belite Bio, Inc. ADR have?

Belite Bio, Inc. ADR has 40,272,144 shares outstanding.

What happened to Belite Bio, Inc. ADR’s price movement after its last earnings report?

Belite Bio, Inc. ADR reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.777. Following the earnings report the stock price went down -7.075%.

Which hedge fund is a major shareholder of Belite Bio, Inc. ADR?

Currently, no hedge funds are holding shares in BLTE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Belite Bio, Inc. ADR Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

406.10%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Belite Bio, Inc. ADR

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.

Belite Bio, Inc. ADR (BLTE) Earnings & Revenues

Historic Earnings Reports

BLTE Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

Overall the call conveyed substantial positive progress: NDA acceptance with priority review and a clear PDUFA date, supportive Phase 3 QAF data, strong cash balance ($780M), a pediatric program, and high patient compliance. Counterbalancing these positives are materially higher R&D and SG&A expenses, a widening net loss, a confidential one‑time royalty payment, limited disclosure on manufacturing inspection status, and a delayed GA interim readout. The positives (regulatory momentum, strong efficacy signal, and financial runway) outweigh the operational and expense-related concerns.View all BLTE earnings summaries

BLTE Stock 12 Month Forecast

Average Price Target

$230.43

▲(47.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"64":"$64","124":"$124","184":"$184","244":"$244","304":"$304"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":303,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$303.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":230.42857142857144,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$230.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$200.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[64,124,184,244,304],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,156.7,167.95384615384614,179.2076923076923,190.46153846153845,201.7153846153846,212.96923076923076,224.22307692307692,235.47692307692307,246.73076923076923,257.9846153846154,269.23846153846154,280.4923076923077,291.74615384615385,{"y":303,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,156.7,162.37142857142857,168.04285714285714,173.71428571428572,179.38571428571427,185.05714285714285,190.72857142857143,196.4,202.07142857142858,207.74285714285713,213.4142857142857,219.0857142857143,224.75714285714287,{"y":230.42857142857144,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,156.7,160.0307692307692,163.36153846153846,166.69230769230768,170.02307692307693,173.35384615384615,176.68461538461537,180.01538461538462,183.34615384615384,186.67692307692306,190.0076923076923,193.33846153846153,196.66923076923078,{"y":200,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":65.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.96,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.31,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.58,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.25,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.85,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":142.31,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.61,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.7,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >